Celldex Therapeutics announces positive data from pilot study of CDX-301
Celldex announced promising early data from an investigator-initiated pilot study evaluating the combination of CDX-301 and stereotactic body radiotherapy in patients with advanced non-small cell lung cancer. CDX‑301 (recombinant human Flt3 ligand) is a potent hematopoietic cytokine. April 20, 2018